Details

Autor(en) / Beteiligte

• Morales-Múnera, C.
• Vilarrasa, E.
• Puig, L.

Titel

Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

Ist Teil von

• British journal of dermatology (1951), 2013-04, Vol.168 (4), p.820-824

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Background Palmoplantar pustulosis (PPP) is characterized by sterile pustules with hyperkeratosis, erythema, scaling and fissuring on the palms and soles. PPP can present alone, or in association with palmoplantar pustular psoriasis (PPPP). Objectives To examine treatment with ustekinumab in patients with severe refractory PPPP. Methods Five patients (two men and three women, age 30–50 years) with severe refractory PPPP were treated with ustekinumab, according to a pre‐established protocol. A 45 mg dose of ustekinumab was administered subcutaneously, followed by a 45 mg dose 4 weeks later and every 12 weeks thereafter. The severity of involvement and the therapeutic outcome were evaluated in every patient before, during and after treatment. Results Positive responses to ustekinumab were initially seen in all of the patients 2–3 weeks after the first dose, and were more remarkable after the second injection. Complete resolution of PPPP was achieved at week 20 and was maintained in all patients. Conclusions Ustekinumab appears to be an effective and safe therapeutic option in PPPP, leading to complete or nearly complete resolution of lesions and a significant improvement in patients’ quality of life. What’s already known about this topic? •  There is no standard treatment for palmoplantar pustular psoriasis (PPPP), and dermatologists have used treatments for psoriasis with varied results. •  Innovative biological agents have recently been introduced in the treatment of moderate‐to‐severe psoriasis vulgaris, and their efficacy has been shown in nonpustular palmoplantar psoriasis in sporadic case reports and very small series. What does this study add? •  Ustekinumab appears to be an effective and safe therapeutic option in PPPP, leading to complete or nearly complete resolution of the lesions, with a significant improvement in patients’ health‐related quality of life.